 Cortexyme NASDAQ:CRTX was downgraded by Zacks Investment Research from a hold rating to a sell rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, Cortexyme Inc. is a clinical-stage biopharmaceutical company. It is focused on providing disease-modifying therapeutics to treat Alzheimers and other degenerative diseases. The companys ... 